Alkermes ALKS
NASDAQ ALKS
$45.37 -0.13 (-0.27%)
As of: Sep 9, 2026 · 3:26 PM EDT

Alkermes (ALKS) Total Current Liabilities (2011 - 2026)

Alkermes' (ALKS) quarterly Total Current Liabilities came in at $662.1 million in Q2 2026, up 30.86% year-over-year from $506.0 million in Q2 2025, and up 10.44% quarter-over-quarter from $599.5 million in Q1 2026.

Analysis

Alkermes (ALKS) Total Current Liabilities (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Total Current Liabilities for 16 consecutive years, with $662.1 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Total Current Liabilities rose 30.86% year-over-year to $662.1 million in Q2 2026; TTM through Jun 2026 was $662.1 million, a 30.86% increase from a year earlier, with the FY2025 full-year figure at $543.4 million, up 16.82% from the prior year.
  • Total Current Liabilities was $662.1 million for Q2 2026 at Alkermes, up from $599.5 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $662.1 million in Q2 2026 and troughed at $438.5 million in Q2 2022.
  • A 5-year average of $499.7 million and a median of $490.0 million in 2023 frame the typical range for Total Current Liabilities.
  • Across the five-year window, Total Current Liabilities decreased 10.58% in 2024 and jumped 35.1% in 2026, its largest moves.
  • Over 5 years, Total Current Liabilities stood at $497.7 million in 2022, then rose by 4.52% to $520.2 million in 2023, then retreated by 10.58% to $465.2 million in 2024, then increased by 16.82% to $543.4 million in 2025, then grew by 21.83% to $662.1 million in 2026.
  • The last three Total Current Liabilities figures came in at $662.1 million (Q2 2026), $599.5 million (Q1 2026), and $543.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Johnson & Johnson 645.93 Bn 625.17 Bn 17.26 Bn 54.90 Bn
2 AbbVie 443.06 Bn 436.49 Bn 12.70 Bn 41.64 Bn
3 Merck 365.76 Bn 358.62 Bn 12.21 Bn 27.73 Bn
4 Novartis Ag 266.47 Bn 258.78 Bn 11.24 Bn 31.75 Bn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 32.65 Bn
6 Sanofi 52.36 Bn 44.98 Bn 10.79 Bn 37.11 Bn
7 Revolution Medicines 43.97 Bn 43.97 Bn - 354.06 Mn
8 Incyte 25.42 Bn 20.88 Bn 1.57 Bn 1.31 Bn
9 United Therapeutics 21.52 Bn 18.86 Bn 683.80 Mn 607.80 Mn
10 Alkermes 7.58 Bn 6.93 Bn 397.90 Mn 662.09 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 662.09 Mn
Mar 31, 2026 599.50 Mn
Dec 31, 2025 543.44 Mn
Sep 30, 2025 474.36 Mn
Jun 30, 2025 505.96 Mn
Mar 31, 2025 443.73 Mn
Dec 31, 2024 465.20 Mn
Sep 30, 2024 453.71 Mn
Jun 30, 2024 515.55 Mn
Mar 31, 2024 458.98 Mn
Dec 31, 2023 520.22 Mn
Sep 30, 2023 503.11 Mn
Jun 30, 2023 487.19 Mn
Mar 31, 2023 492.91 Mn
Dec 31, 2022 497.74 Mn
Sep 30, 2022 469.56 Mn
Jun 30, 2022 438.52 Mn
Mar 31, 2022 462.36 Mn
Dec 31, 2021 471.29 Mn
Sep 30, 2021 452.98 Mn